MinnesotaPrevention Quality Measures Compared to Achievable Benchmarks

The NHQDR quality measures specific to Prevention are compared to achievable benchmarks, which are derived from the top-performing States. Better performance of a State can mean higher or lower values of a measure, depending on the desired outcome. For example, low values are desirable for measures such as infant mortality, whereas high values are desirable for measures such as preventative screening. The categories of achievement have been standardized across the measure definitions so that:

 
Far away from benchmark - a State's value for a measure has not achieved 50% of the benchmark.
 
Close to benchmark - a State's value for a measure is between 50% and 90% of a benchmark (i.e., worse than the benchmark but has achieved at least half of the benchmark but not as much as 90% of a benchmark).
 
Achieved benchmark or better - a State's value for a measure is no worse than 90% of the benchmark value, the measure has achieved the benchmark. This category also includes the case in which the measure’s value is equal to or better than the benchmark.
Measures That Achieved Benchmark or Better
Measure Estimate Benchmark Distance to Benchmark
Children ages 19-35 months who received 3 or more doses of hepatitis B vaccine 95.2 96.4 1.2%
Home health patients who had influenza vaccination during flu season 83.5 84.8 1.5%
Children ages 19-35 months who received 3 or more doses of polio vaccine 95.7 97.3 1.6%
Long-stay nursing home patients who were assessed and appropriately given the seasonal influenza vaccine 92.1 94.1 2.1%
Adults age 65 and over who ever received pneumococcal vaccination 77.0 78.7 2.2%
Short-stay nursing home patients who had flu vaccination appropriately given 90.7 92.9 2.4%
Long-stay nursing home residents who were assessed for pneumococcal vaccination 95.6 98.0 2.4%
Children ages 19-35 months who received 1 or more doses of varicella vaccine 93.1 95.7 2.8%
Adults ages 18-64 at high risk (e.g., COPD) who received an influenza vaccination in the last flu season 46.4 47.8 2.9%
Short-stay nursing home residents who were assessed for pneumococcal vaccination 92.5 95.3 2.9%
Children ages 19-35 months who received 4 or more doses of diphtheria-tetanus-pertussis vaccine 87.1 90.6 3.9%
Home health patients who had pneumococcal polysaccharide vaccination 82.4 86.1 4.3%
Adolescents ages 13-15 who received 1 or more doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since the age of ten years 91.0 95.2 4.4%
Children ages 19-35 months who received 1 or more doses of measles-mumps-rubella vaccine 92.0 96.4 4.5%
Adolescents ages 13-15 who received 1 or more doses of meningococcal conjugate vaccine 89.6 95.4 6.1%
Adults age 65 and over who received an influenza vaccination in the last flu season 65.4 70.3 7.0%
Adults who received a blood cholesterol measurement in the last 5 years 76.4 82.3 7.1%
Adolescents ages 16-17 who received 1 or more doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since the age of ten years 87.7 95.9 8.6%
Measures That Are Close to Benchmark
Measure Estimate Benchmark Distance to Benchmark
Breast cancer diagnosed at advanced stage (regional, distant stage, or local stage with tumor greater than 2 cm) per 100,000 women age 40 and over 81.0 72.8 11.3%
Cervical cancer diagnosed at advanced stage (all invasive tumors) per 100,000 women age 20 and over 8.7 7.6 15.1%
Adolescents ages 16-17 who received 1 or more doses of meningococcal conjugate vaccine 78.4 96.2 18.5%
Adults ages 18-64 at high risk (e.g., COPD) who ever received pneumococcal vaccination 36.3 44.8 19.0%
Colorectal cancer diagnosed at advanced stage (tumors diagnosed at regional or distant stage) per 100,000 population age 50 and over 58.4 47.2 23.8%
Measures With No Available Benchmark Information or Supplemental Measures
Measure Estimate Benchmark Distance to Benchmark
Composite measure: Children ages 19-35 months who received all recommended vaccines 73.8
Adolescent aged 13-15 years who received 3 or more doses of human papillomavirus (HPV) vaccine 30.9
Adolescent ages 16-17 years who received 3 or more doses of human papillomavirus (HPV) vaccine 43.0
Adolescents ages 13-15 years (excluding adolescents who have had varicella) vaccinated with at least 2 doses of varicella 88.0